Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

196 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating RET Alterations and Oncogenic Signaling Pathway Aberrations.
Rich TA, Reckamp KL, Chae YK, Doebele RC, Iams WT, Oh M, Raymond VM, Lanman RB, Riess JW, Stinchcombe TE, Subbiah V, Trevarthen DR, Fairclough S, Yen J, Gautschi O. Rich TA, et al. Among authors: stinchcombe te. Clin Cancer Res. 2019 Oct 1;25(19):5832-5842. doi: 10.1158/1078-0432.CCR-18-4049. Epub 2019 Jul 12. Clin Cancer Res. 2019. PMID: 31300450 Free PMC article.
KRAS mutation: should we test for it, and does it matter?
Roberts PJ, Stinchcombe TE. Roberts PJ, et al. Among authors: stinchcombe te. J Clin Oncol. 2013 Mar 10;31(8):1112-21. doi: 10.1200/JCO.2012.43.0454. Epub 2013 Feb 11. J Clin Oncol. 2013. PMID: 23401440 Review.
Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance).
Edelman MJ, Wang X, Hodgson L, Cheney RT, Baggstrom MQ, Thomas SP, Gajra A, Bertino E, Reckamp KL, Molina J, Schiller JH, Mitchell-Richards K, Friedman PN, Ritter J, Milne G, Hahn OM, Stinchcombe TE, Vokes EE; Alliance for Clinical Trials in Oncology. Edelman MJ, et al. Among authors: stinchcombe te. J Clin Oncol. 2017 Jul 1;35(19):2184-2192. doi: 10.1200/JCO.2016.71.3743. Epub 2017 May 10. J Clin Oncol. 2017. PMID: 28489511 Free PMC article. Clinical Trial.
Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non-Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers.
Peters S, Stahel R, Bubendorf L, Bonomi P, Villegas A, Kowalski DM, Baik CS, Isla D, Carpeno JC, Garrido P, Rittmeyer A, Tiseo M, Meyenberg C, de Haas S, Lam LH, Lu MW, Stinchcombe TE. Peters S, et al. Among authors: stinchcombe te. Clin Cancer Res. 2019 Jan 1;25(1):64-72. doi: 10.1158/1078-0432.CCR-18-1590. Epub 2018 Sep 11. Clin Cancer Res. 2019. PMID: 30206164 Clinical Trial.
Identification of osimertinib-resistant EGFR L792 mutations by cfDNA sequencing: oncogenic activity assessment and prevalence in large cfDNA cohort.
Fairclough SR, Kiedrowski LA, Lin JJ, Zelichov O, Tarcic G, Stinchcombe TE, Odegaard JI, Lanman RB, Shaw AT, Nagy RJ. Fairclough SR, et al. Among authors: stinchcombe te. Exp Hematol Oncol. 2019 Oct 11;8:24. doi: 10.1186/s40164-019-0148-7. eCollection 2019. Exp Hematol Oncol. 2019. PMID: 31632838 Free PMC article.
Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non-Small Cell Lung Cancer Survival.
Zhao YC, Tang D, Yang S, Liu H, Luo S, Stinchcombe TE, Glass C, Su L, Shen S, Christiani DC, Wei Q. Zhao YC, et al. Among authors: stinchcombe te. Cancer Epidemiol Biomarkers Prev. 2020 Aug;29(8):1679-1688. doi: 10.1158/1055-9965.EPI-19-1450. Epub 2020 Jun 3. Cancer Epidemiol Biomarkers Prev. 2020. PMID: 32493705 Free PMC article.
Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC.
Stinchcombe TE, Doebele RC, Wang X, Gerber DE, Horn L, Camidge DR. Stinchcombe TE, et al. J Thorac Oncol. 2021 Jan;16(1):156-161. doi: 10.1016/j.jtho.2020.09.018. Epub 2020 Oct 8. J Thorac Oncol. 2021. PMID: 33039599 Free article. Clinical Trial.
Phase IB Study of Osimertinib in Combination with Navitoclax in EGFR-mutant NSCLC Following Resistance to Initial EGFR Therapy (ETCTN 9903).
Bertino EM, Gentzler RD, Clifford S, Kolesar J, Muzikansky A, Haura EB, Piotrowska Z, Camidge DR, Stinchcombe TE, Hann C, Malhotra J, Villaruz LC, Paweletz CP, Lau CL, Sholl L, Takebe N, Moscow JA, Shapiro GI, Jänne PA, Oxnard GR. Bertino EM, et al. Among authors: stinchcombe te. Clin Cancer Res. 2021 Mar 15;27(6):1604-1611. doi: 10.1158/1078-0432.CCR-20-4084. Epub 2020 Dec 29. Clin Cancer Res. 2021. PMID: 33376097 Free PMC article. Clinical Trial.
NTRK1 Fusions identified by non-invasive plasma next-generation sequencing (NGS) across 9 cancer types.
Rolfo C, Drilon A, Hong D, McCoach C, Dowlati A, Lin JJ, Russo A, Schram AM, Liu SV, Nieva JJ, Nguyen T, Eshaghian S, Morse M, Gettinger S, Mobayed M, Goldberg S, Araujo-Mino E, Vidula N, Bardia A, Subramanian J, Sashital D, Stinchcombe T, Kiedrowski L, Price K, Gandara DR. Rolfo C, et al. Br J Cancer. 2022 Feb;126(3):514-520. doi: 10.1038/s41416-021-01536-1. Epub 2021 Sep 3. Br J Cancer. 2022. PMID: 34480094 Free PMC article.
196 results